Buradasınız

Anjiyotensin Dönüştürücü Enzim Inhibitörleri ile Anjiyotensin Reseptör Blokerleri Arasındaki Farklar Nelerdir?

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: Are They Different?

Journal Name:

Publication Year:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
The blockage of renin-angiotensin system have both cardiac and renal protective effects beyond reducing the blood pressure. For this reason, similarities and differences between angiotensin receptor antagonists and angiotensin converting enzyme inhibitors should be known. The main difference between the groups is the mechanism of their effects. Inhibition of converting enzyme decreases angiotensin levels but formation of angiotensin II occurs through enzymes other than converting enzyme. Angiotensin II receptor blockers act through binding to the receptor. In addition, inhibition of converting enzyme prevents degradation of bradykinin. This effect was thought to be underlying reason of side effects limiting the drug usage. The information about different and additive effects of both groups will lead the opportunities to block renin-angiotensin system effectively with new strategies including combination of these groups.
Abstract (Original Language): 
Renin-anjiyotensin sisteminin blokajının kan basıncını düşürmesinin ötesinde vasküler, kardiyak ve renal koruyucu etkileri vardır. Bu özellikleri nedeniyle, sistemi bloke eden anjiyotensin dönüştürücü enzim inhibitörleri ile anjiyotensin reseptör blokerlerinin benzerlikleri ve farklı yönlerinin bilinmesi hayati önem taşır. İki grup arasındaki en önemli fark etki mekanizmalarıdır. Dönüştürücü enzimin inhibe edilmesi anjiyotensin H'yi azaltmakla birlikte, dönüştürücü enzim dtşı enzimlerle anjiyotensin II oluşumu olmaktadır. Anjiyotensin II reseptör blokerleri ise direkt reseptöre bağlanarak etki yapar. Ayrıca, dönüştürücü enzim inhibisyonıı ise bradikininin parçalanmasını önleyerek farklı bir etki ortaya koyar. Öte yandan, bu etkinin ilacın kullanımını kısıtlayan yan etkilere neden olduğu da düşünülür. Bu iki ilaç grubunun farkları ve aditif etkileri düşünülerek kombinasyonları da dahil yeni stratejilerin kullanılması renin-anjiyotensin sisteminin daha etkin blokajı imkânın» doğuracaktır.
FULL TEXT (PDF): 

REFERENCES

References: 

i Masry SG.
Glassock RJ (eds). Textbook of Nephrology. Iippİncoti Williams Wilkins. 2001, pp; 169-no.
2. Faforis ü. Yamada II. Jackson CR, et al. Characterization ofçardi-ac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats. Br J Pharmacol 1990 Jul;10fX3): 651-655.
3. The Heart Outcomes Prevention Evaluation Study Investigators. Meets of an angiotensin-converting-en/.ynie inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2090-342:145-153,
i. Henri Outcomes Prevention Evaluation (HOPE) Study Invesli-gaiors. Effects of ramipril on cardiovascular and microvascular oulcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE subsludy Lancet.2000;355:253-39.
% Opie, U I. Drugs for the Heart (5th eel). 2001. p 115. (1 Opie. LH. Drugs for the Heart (5th ed). 2001, p 118.
7. Biollaz J, Brunner 1IR. Gavras 1, et al. Antihypertensive therapy with MK 421: angiotensin II—renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982 Nov-Dec;4(6):966-972.
8. de Gasparo M, Call KJ, lnagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000 Sep;52(3H 15-472.
9. Siragy MH, Carey RM. Angiotensin type 2 receptors: potential importance in the regulation of blood pressure curr. Opinion in nephrology and hypertension 2001, 10:99-103.
10. Masıy SG, Glassock RJ (eds). Textbook of Nephrology, I.ippincott Williams Wilkins, 2001. pp: 169-170.
11. Brown NJ, Kumar S, Painter CA, et al. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PA1-1 over time. Hypertension 2002 Dec;40(6):859-865.
12. Wilmink HW, Banga JD, Hijmering M, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin İI type 1 receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 1999Jul;34(l);140-145.
13- Cohn JN, Tognoni G. Glazer R, et al. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail 2000 Dec;2(4):439.
14. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
15. Pitt. B, Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582.
16. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 2003 May 21 ;289(19): 2560-2572.
17. Edmund JL, Lawrence GH, William RC, et al. Renoproiective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
18. Brenner BM, Cooper ME, Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
19. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised conlrol-led trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000 Dec 9;321(7274): 1440-1444.

Thank you for copying data from http://www.arastirmax.com